{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:01:34Z","timestamp":1793152894303,"version":"4.5.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Impot Res"],"DOI":"10.1038\/s41443-026-01237-4","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T10:20:57Z","timestamp":1770805257000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cardiovascular and prostate cancer risk associated to testosterone replacement therapy \u2013 a systematic review and meta-analysis of 41 randomized controlled trials"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2838-6251","authenticated-orcid":false,"given":"Carlos A.","family":"Garc\u00eda-Becerra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4433-5345","authenticated-orcid":false,"given":"Maria I.","family":"Arias-Gallardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5027-7540","authenticated-orcid":false,"given":"Jes\u00fas E.","family":"Ju\u00e1rez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ver\u00f3nica","family":"Soltero-Molinar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis F.","family":"Parra-Cama\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariabelen I.","family":"Rivera-Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Garc\u00eda-Becerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos M.","family":"Garc\u00eda-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"1237_CR1","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1111\/andr.12850","volume":"8","author":"VA Giagulli","year":"2020","unstructured":"Giagulli VA, Castellana M, Lisco G, Triggiani V. Critical evaluation of different available guidelines for late-onset hypogonadism. Andrology. 2020;8:1628\u201341.","journal-title":"Andrology"},{"key":"1237_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ecl.2021.11.016","volume":"51","author":"A Thirumalai","year":"2022","unstructured":"Thirumalai A, Anawalt BD. Epidemiology of male hypogonadism. Endocrinol Metab Clin North Am. 2022;51:1\u201327.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"1237_CR3","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/nrurol.2014.338","volume":"12","author":"L Klotz","year":"2015","unstructured":"Klotz L. Testosterone therapy and prostate cancer-safety concerns are well founded. Nat Rev Urol. 2015;12:48\u201354.","journal-title":"Nat Rev Urol"},{"key":"1237_CR4","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/j.1464-410X.2011.10755.x","volume":"110","author":"CCK Ho","year":"2012","unstructured":"Ho CCK, Tong SF, Low WY, Ng CJ, Khoo EM, Lee VKM, et al. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU Int. 2012;110:260\u20135.","journal-title":"BJU Int"},{"key":"1237_CR5","doi-asserted-by":"crossref","unstructured":"Basaria S, Coviello Andrea D, Travison Thomas G, Storer Thomas W, Farwell Wildon R, Jette Alan M, et al. Adverse events associated with testosterone administration. N Engl J Med. 363:109\u201322.","DOI":"10.1056\/NEJMoa1000485"},{"key":"1237_CR6","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa2215025","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023;389:107\u201317.","journal-title":"N Engl J Med"},{"key":"1237_CR7","doi-asserted-by":"publisher","first-page":"e2348692","DOI":"10.1001\/jamanetworkopen.2023.48692","volume":"6","author":"S Bhasin","year":"2023","unstructured":"Bhasin S, Travison TG, Pencina KM, O\u2019Leary M, Cunningham GR, Lincoff AM, et al. Prostate safety events during testosterone replacement therapy in men with hypogonadism: a randomized clinical trial. JAMA Netw Open. 2023;6:e2348692.","journal-title":"JAMA Netw Open"},{"key":"1237_CR8","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1001\/archsurg.1941.01210140043004","volume":"43","author":"C Huggins","year":"1941","unstructured":"Huggins C, Stevens RE, Hodges CV. Studies on prostatic cancer: II. the effects of castration on advanced carcinoma of the prostate gland. Arch Surg. 1941;43:209\u201323.","journal-title":"Arch Surg"},{"key":"1237_CR9","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.eururo.2008.09.024","volume":"55","author":"A Morgentaler","year":"2009","unstructured":"Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol. 2009;55:310\u201320.","journal-title":"Eur Urol"},{"key":"1237_CR10","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"1237_CR11","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","volume":"40","author":"JI Epstein","year":"2016","unstructured":"Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA, et al. The 2014 international society of urological pathology (isup) consensus conference on gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016;40:244\u201352.","journal-title":"Am J Surg Pathol"},{"key":"1237_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-5-13","volume":"5","author":"SP Hozo","year":"2005","unstructured":"Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5:13.","journal-title":"BMC Med Res Methodol"},{"key":"1237_CR13","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"1237_CR14","doi-asserted-by":"publisher","first-page":"e172","DOI":"10.1161\/CIR.0000000000000523","volume":"136","author":"G Rao","year":"2017","unstructured":"Rao G, Lopez-Jimenez F, Boyd J, D\u2019Amico F, Durant NH, Hlatky MA, et al. Methodological standards for meta-analyses and qualitative systematic reviews of cardiac prevention and treatment studies: a scientific statement from the american heart association. Circulation. 2017;136:e172\u201394.","journal-title":"Circulation"},{"key":"1237_CR15","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3102\/10769986030003261","volume":"30","author":"W Viechtbauer","year":"2005","unstructured":"Viechtbauer W. Bias and efficiency of meta-analytic variance estimators in the random-effects model. J Educ Behav Stat. 2005;30:261\u201393.","journal-title":"J Educ Behav Stat"},{"key":"1237_CR16","doi-asserted-by":"publisher","first-page":"e010983","DOI":"10.1136\/bmjopen-2015-010983","volume":"6","author":"J Cheng","year":"2016","unstructured":"Cheng J, Pullenayegum E, Marshall JK, Iorio A, Thabane L. Impact of including or excluding both-armed zero-event studies on using standard meta-analysis methods for rare event outcome: a simulation study. BMJ Open. 2016;6:e010983.","journal-title":"BMJ Open"},{"key":"1237_CR17","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1001\/jama.296.19.2351","volume":"296","author":"LS Marks","year":"2006","unstructured":"Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JI, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA. 2006;296:2351\u201361.","journal-title":"JAMA"},{"key":"1237_CR18","first-page":"B5396","volume":"64","author":"LV Magnussen","year":"2017","unstructured":"Magnussen LV. Testosterone therapy of men with type 2 diabetes mellitus - a randomized, double-blinded, placebo-controlled study. Dan Med J. 2017;64:B5396.","journal-title":"Dan Med J"},{"key":"1237_CR19","doi-asserted-by":"crossref","unstructured":"Snyder Peter J, Bhasin S, Cunningham Glenn R, Matsumoto Alvin M, Stephens-Shields Alisa J, Cauley Jane A, et al. Effects of testosterone treatment in older men. N Engl J Med. 374:611\u201324.","DOI":"10.1056\/NEJMoa1506119"},{"key":"1237_CR20","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1001\/jama.2015.8881","volume":"314","author":"S Basaria","year":"2015","unstructured":"Basaria S, Harman SM, Travison TG, Hodis H, Tsitouras P, Budoff M, et al. Effects of testosterone administration for 3 years on subclinical atherosclerosis progression in older men with low or low-normal testosterone levels: a randomized clinical trial. JAMA. 2015;314:570\u201381.","journal-title":"JAMA"},{"key":"1237_CR21","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1097\/01.j.pain.0000460308.86819.aa","volume":"156","author":"S Basaria","year":"2015","unstructured":"Basaria S, Travison TG, Alford D, Knapp PE, Teeter K, Cahalan C, et al. Effects of testosterone replacement in men with opioid-induced androgen deficiency: a randomized controlled trial. Pain. 2015;156:280\u20138.","journal-title":"Pain"},{"key":"1237_CR22","doi-asserted-by":"publisher","first-page":"e1096","DOI":"10.1210\/clinem\/dgaa917","volume":"106","author":"Y Barnouin","year":"2021","unstructured":"Barnouin Y, Armamento-Villareal R, Celli A, Jiang B, Paudyal A, Nambi V, et al. Testosterone replacement therapy added to intensive lifestyle intervention in older men with obesity and hypogonadism. J Clin Endocrinol Metab. 2021;106:e1096\u2013110.","journal-title":"J Clin Endocrinol Metab"},{"key":"1237_CR23","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1080\/13685538.2018.1468429","volume":"21","author":"K Groti","year":"2018","unstructured":"Groti K, \u017duran I, Antoni\u010d B, For\u0161nari\u010d L, Pfeifer M. The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes. aging Male Off J Int Soc Study. Aging Male. 2018;21:158\u201369.","journal-title":"Aging Male"},{"key":"1237_CR24","doi-asserted-by":"publisher","first-page":"828","DOI":"10.2337\/dc10-1233","volume":"34","author":"TH Jones","year":"2011","unstructured":"Jones TH, Arver S, Behre HM, Buvat J, Meuleman E, Moncada I, et al. Testosterone replacement in hypogonadal men with type 2 diabetes and\/or metabolic syndrome (the TIMES2 study). Diabetes Care. 2011;34:828\u201337.","journal-title":"Diabetes Care"},{"key":"1237_CR25","first-page":"871","volume":"90","author":"CJ Malkin","year":"2004","unstructured":"Malkin CJ, Pugh PJ, Morris PD, Kerry KE, Jones RD, Jones TH, et al. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart Br Card Soc. 2004;90:871\u20136.","journal-title":"Heart Br Card Soc"},{"key":"1237_CR26","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1111\/jsm.12146","volume":"10","author":"G Hackett","year":"2013","unstructured":"Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P. Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. J Sex Med. 2013;10:1612\u201327.","journal-title":"J Sex Med"},{"key":"1237_CR27","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1530\/EJE-08-0634","volume":"160","author":"JJ Legros","year":"2009","unstructured":"Legros JJ, Meuleman EJH, Elbers JMH, Geurts TBP. Kaspers MJGH, Bouloux PMG. Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. Eur J Endocrinol. 2009;160:821\u201331.","journal-title":"Eur J Endocrinol"},{"key":"1237_CR28","doi-asserted-by":"publisher","first-page":"3821","DOI":"10.1210\/jc.2014-1872","volume":"99","author":"EJ Gianatti","year":"2014","unstructured":"Gianatti EJ, Dupuis P, Hoermann R, Zajac JD, Grossmann M. Effect of testosterone treatment on constitutional and sexual symptoms in men with type 2 diabetes in a randomized, placebo-controlled clinical trial. J Clin Endocrinol Metab. 2014;99:3821\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"1237_CR29","first-page":"570","volume":"16","author":"RA Gopal","year":"2010","unstructured":"Gopal RA, Bothra N, Acharya SV, Ganesh HK, Bandgar TR, Menon PS, et al. Treatment of hypogonadism with testosterone in patients with type 2 diabetes mellitus. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2010;16:570\u20136.","journal-title":"Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol"},{"key":"1237_CR30","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1210\/jc.2014-4434","volume":"100","author":"DA Paduch","year":"2015","unstructured":"Paduch DA, Polzer PK, Ni X, Basaria S. Testosterone replacement in androgen-deficient men with ejaculatory dysfunction: a randomized controlled trial. J Clin Endocrinol Metab. 2015;100:2956\u201362.","journal-title":"J Clin Endocrinol Metab"},{"key":"1237_CR31","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/ijo.2016.242","volume":"41","author":"M Ng Tang Fui","year":"2017","unstructured":"Ng Tang Fui M, Hoermann R, Prendergast LA, Zajac JD, Grossmann M. Symptomatic response to testosterone treatment in dieting obese men with low testosterone levels in a randomized, placebo-controlled clinical trial. Int J Obes. 2017;41:420\u20136.","journal-title":"Int J Obes"},{"key":"1237_CR32","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1111\/j.1743-6109.2010.01931.x","volume":"7","author":"A Aversa","year":"2010","unstructured":"Aversa A, Bruzziches R, Francomano D, Rosano G, Isidori AM, Lenzi A, et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. J Sex Med. 2010;7:3495\u2013503.","journal-title":"J Sex Med"},{"key":"1237_CR33","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1111\/j.1743-6109.2011.02630.x","volume":"9","author":"JM Kaufman","year":"2012","unstructured":"Kaufman JM, Miller MG, Fitzpatrick S, McWhirter C, Brennan JJ. One-year efficacy and safety study of a 1.62% testosterone gel in hypogonadal men: results of a 182-day open-label extension of a 6-month double-blind study. J Sex Med. 2012;9:1149\u201361.","journal-title":"J Sex Med"},{"key":"1237_CR34","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1177\/1557988318772734","volume":"12","author":"Y Inoue","year":"2018","unstructured":"Inoue Y, Nakamura K, Kuwahara Y, Lu Y, Masuda N, Horie S, et al. Efficacy of testosterone treatment in hemodialysis patients as assessed by aging males\u2019 symptoms scores: a pilot study. Am J Mens Health. 2018;12:1541\u20137.","journal-title":"Am J Mens Health"},{"key":"1237_CR35","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1046\/j.1365-2265.2001.01297.x","volume":"55","author":"SJ Howell","year":"2001","unstructured":"Howell SJ, Radford JA, Adams JE, Smets EM, Warburton R, Shalet SM. Randomized placebo-controlled trial of testosterone replacement in men with mild Leydig cell insufficiency following cytotoxic chemotherapy. Clin Endocrinol. 2001;55:315\u201324.","journal-title":"Clin Endocrinol"},{"key":"1237_CR36","doi-asserted-by":"publisher","first-page":"e1002960","DOI":"10.1371\/journal.pmed.1002960","volume":"16","author":"JS Walsh","year":"2019","unstructured":"Walsh JS, Marshall H, Smith IL, Greenfield DM, Swain J, Best E, et al. Testosterone replacement in young male cancer survivors: A 6-month double-blind randomised placebo-controlled trial. PLoS Med. 2019;16:e1002960.","journal-title":"PLoS Med"},{"key":"1237_CR37","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1007\/BF03350341","volume":"33","author":"A Aversa","year":"2010","unstructured":"Aversa A, Bruzziches R, Francomano D, Spera G, Lenzi A. Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome. J Endocrinol Invest. 2010;33:776\u201383.","journal-title":"J Endocrinol Invest"},{"key":"1237_CR38","doi-asserted-by":"publisher","first-page":"406","DOI":"10.4088\/JCP.v62n0602","volume":"62","author":"SN Seidman","year":"2001","unstructured":"Seidman SN, Spatz E, Rizzo C, Roose SP. Testosterone replacement therapy for hypogonadal men with major depressive disorder: a randomized, placebo-controlled clinical trial. J Clin Psychiatry. 2001;62:406\u201312.","journal-title":"J Clin Psychiatry"},{"key":"1237_CR39","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1001\/archneur.63.5.729","volume":"63","author":"MS Okun","year":"2006","unstructured":"Okun MS, Fernandez HH, Rodriguez RL, Romrell J, Suelter M, Munson S, et al. Testosterone therapy in men with parkinson disease: results of the TEST-PD Study. Arch Neurol. 2006;63:729\u201335.","journal-title":"Arch Neurol"},{"key":"1237_CR40","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.juro.2015.10.083","volume":"195","author":"G Brock","year":"2016","unstructured":"Brock G, Heiselman D, Maggi M, Kim SW, Rodr\u00edguez Vallejo JM, Behre HM, et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. J Urol. 2016;195:699\u2013705.","journal-title":"J Urol"},{"key":"1237_CR41","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/tam.6.1.13.17","volume":"6","author":"RS Tan","year":"2003","unstructured":"Tan RS, Pu SJ. A pilot study on the effects of testosterone in hypogonadal aging male patients with Alzheimer\u2019s disease. Aging Male. 2003;6:13\u20137.","journal-title":"Aging Male"},{"key":"1237_CR42","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/S2213-8587(20)30367-3","volume":"9","author":"G Wittert","year":"2021","unstructured":"Wittert G, Bracken K, Robledo KP, Grossmann M, Yeap BB, Handelsman DJ, et al. Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial. Lancet Diabetes Endocrinol. 2021;9:32\u201345.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1237_CR43","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1530\/eje.1.02166","volume":"154","author":"D Kapoor","year":"2006","unstructured":"Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;154:899\u2013906.","journal-title":"Eur J Endocrinol"},{"key":"1237_CR44","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/JCP.0b013e3181d207ca","volume":"30","author":"HGJ Pope","year":"2010","unstructured":"Pope HGJ, Amiaz R, Brennan BP, Orr G, Weiser M, Kelly JF, et al. Parallel-group placebo-controlled trial of testosterone gel in men with major depressive disorder displaying an incomplete response to standard antidepressant treatment. J Clin Psychopharmacol. 2010;30:126\u201334.","journal-title":"J Clin Psychopharmacol"},{"key":"1237_CR45","unstructured":"The Cardiac Benefit of Androgen Replacement in Hypogonadal Males With Coronary Artery Disease Following Successful Percutaneous Coronary Intervention (PCI). 2006 [cited 2007 Jan 1]. https:\/\/clinicaltrials.gov\/study\/NCT00413244."},{"key":"1237_CR46","unstructured":"Exercise and Testosterone Therapy in Elderly Men With Physical Frailty. 2006 [cited 2004 Nov 1]. https:\/\/clinicaltrials.gov\/study\/NCT00345969."},{"key":"1237_CR47","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.clgc.2022.04.017","volume":"20","author":"M Kreiberg","year":"2022","unstructured":"Kreiberg M, J\u00f8rgensen N, Juul A, Lauritsen J, Oturai P, Helge JW, et al. A randomized double-blind single center study of testosterone replacement therapy or placebo in testicular cancer survivors with mild Leydig cell insufficiency (Einstein-intervention). Clin Genitourin Cancer. 2022;20:404\u201314.","journal-title":"Clin Genitourin Cancer"},{"key":"1237_CR48","unstructured":"The Effects of Cyclic Testosterone Administration on Muscle Function in Older Individuals. 2009 [cited 2006 Jan 1]. https:\/\/clinicaltrials.gov\/study\/NCT00957528."},{"key":"1237_CR49","unstructured":"Effect of Hypogonadotrophic Hypogonadism and Treatment With Testosterone on Insulin Sensitivity, Inflammation, Body Composition and Sexual Function in Obese and Type 2 Diabetic Men. 2010 [cited 2010 May 1]. https:\/\/clinicaltrials.gov\/study\/NCT01127659."},{"key":"1237_CR50","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1210\/jc.2012-3695","volume":"98","author":"KL Hildreth","year":"2013","unstructured":"Hildreth KL, Barry DW, Moreau KL, Vande Griend J, Meacham RB, Nakamura T, et al. Effects of testosterone and progressive resistance exercise in healthy, highly functioning older men with low-normal testosterone levels. J Clin Endocrinol Metab. 2013;98:1891\u2013900.","journal-title":"J Clin Endocrinol Metab"},{"key":"1237_CR51","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1001\/archneur.63.2.nct50002","volume":"63","author":"PH Lu","year":"2006","unstructured":"Lu PH, Masterman DA, Mulnard R, Cotman C, Miller B, Yaffe K, et al. Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men. Arch Neurol. 2006;63:177\u201385.","journal-title":"Arch Neurol"},{"key":"1237_CR52","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1007\/s40618-022-01776-9","volume":"45","author":"G Rastrelli","year":"2022","unstructured":"Rastrelli G, Cipriani S, Lotti F, Cellai I, Comeglio P, Filippi S, et al. Testosterone does not affect lower urinary tract symptoms while improving markers of prostatitis in men with benign prostatic hyperplasia: a randomized clinical trial. J Endocrinol Invest. 2022;45:1413\u201325.","journal-title":"J Endocrinol Invest"},{"key":"1237_CR53","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/j.1365-2605.2005.00612.x","volume":"29","author":"Z Merza","year":"2006","unstructured":"Merza Z, Blumsohn A, Mah PM, Meads DM, McKenna SP, Wylie K, et al. Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism. Int J Androl. 2006;29:381\u201391.","journal-title":"Int J Androl"},{"key":"1237_CR54","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1053\/j.ajkd.2005.10.022","volume":"47","author":"AT Brockenbrough","year":"2006","unstructured":"Brockenbrough AT, Dittrich MO, Page ST, Smith T, Stivelman JC, Bremner WJ. Transdermal androgen therapy to augment EPO in the treatment of anemia of chronic renal disease. Am J Kidney Dis Off J Natl Kidney Found. 2006;47:251\u201362.","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"key":"1237_CR55","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.pcad.2024.04.001","volume":"85","author":"V Jaiswal","year":"2024","unstructured":"Jaiswal V, Sawhney A, Nebuwa C, Borra V, Deb N, Halder A, et al. Association between testosterone replacement therapy and cardiovascular outcomes: a meta-analysis of 30 randomized controlled trials. Prog Cardiovasc Dis. 2024;85:45\u201353.","journal-title":"Prog Cardiovasc Dis"},{"key":"1237_CR56","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/pcan.2013.60","volume":"17","author":"Y Cui","year":"2014","unstructured":"Cui Y, Zong H, Yan H, Zhang Y. The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2014;17:132\u201343.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1237_CR57","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1016\/j.juro.2011.05.082","volume":"186","author":"H Botto","year":"2011","unstructured":"Botto H, Neuzillet Y, Lebret T, Camparo P, Molinie V, Raynaud JP. High incidence of predominant Gleason pattern 4 localized prostate cancer is associated with low serum testosterone. J Urol. 2011;186:1400\u20135.","journal-title":"J Urol"},{"key":"1237_CR58","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1161\/CIRCULATIONAHA.124.071117","volume":"151","author":"J Windfeld-Mathiasen","year":"2025","unstructured":"Windfeld-Mathiasen J, Heerfordt IM, Dalhoff KP, Andersen JT, Andersen MA, Johansson KS, et al. Cardiovascular disease in anabolic androgenic steroid users. Circulation. 2025;151:828\u201334.","journal-title":"Circulation"}],"container-title":["International Journal of Impotence Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41443-026-01237-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41443-026-01237-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41443-026-01237-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:03:26Z","timestamp":1789052606000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41443-026-01237-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":58,"alternative-id":["1237"],"URL":"https:\/\/doi.org\/10.1038\/s41443-026-01237-4","relation":{},"ISSN":["0955-9930","1476-5489"],"issn-type":[{"value":"0955-9930","type":"print"},{"value":"1476-5489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"20 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In compliance with ethical standards, authors declare that there is not a single conflict of interest to declare.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}